Theranostics Treatments
What disease sites are treated with theranostics?
While there are several new FDA-Approved radiopharmaceutical drugs designed for theranostics to treat cancers such as prostate, neuroendocrine, thyroid, and more, Pluvicto is currently offered at Provision Theranostics Center to treat advanced prostate cancer.
What is Pluvicto?
It's not chemotherapy. Its targeted treatment called radioligand therapy (RLT) for PSMA+ mCRPC.
Who is a candidate for Pluvicto?
Pluvicto could be right for you if you have PSMA positive metastatic castrate resistant prostate cancer and have failed either hormone therapy or a combination of hormone therapy and chemotherapy.
Get Your PSMA PET/CT Scan at Provision Diagnostic Imaging.
How do I schedule a consultation to speak to a physician about Pluvicto?
Contact Provision Theranostics Center to schedule a consultation, with our Board-Certified Radiation Oncologists, authorized to administer radiopharmaceuticals.
Phone: (865) 437-5252
Fax: (865) 269-3056
How does theranostics with Pluvicto work?
Utilizing PET/CT imaging, a PSMA radiotracer locates the Prostate Cancer, illuminating its exact location on the scan. The Radiologist can see the cancer and make a diagnosis for treatment. Prescribed treatment can follow with a higher-dose radiotracer infusion of Pluvicto, to target and kill the cancer, while leaving healthy cells and tissue largely spared from damage. Theranostic treatments are administered by a board-certified Radiation Oncologist, who customizes and monitors results closely with SPECT/CT scans, PET/CT scans, and lab work after each treatment.